# OnCo record nintedanib (drug). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix owl: <http://www.w3.org/2002/07/owl#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/drugs/nintedanib/>
  a schema:Drug ;
  onco:kind "drug" ;
  schema:identifier "nintedanib" ;
  schema:name "Nintedanib"@en ;
  schema:description "Nintedanib is a triple angiokinase inhibitor pill (VEGFR, FGFR, PDGFR) approved for pulmonary fibrosis and, in the EU, for second-line lung adenocarcinoma with docetaxel. In mesothelioma the phase 2 part of LUME-Meso suggested slower progression in epithelioid disease, but the phase 3 part showed none, a much-cited warning about small randomised phase 2 signals."@en ;
  schema:url <https://onco.cc/drugs/nintedanib/> ;
  schema:dateModified "2026-09-07"^^xsd:date ;
  schema:sameAs <https://en.wikipedia.org/wiki/Nintedanib> ;
  owl:sameAs <http://www.wikidata.org/entity/Q15149723> ;
  schema:citation <https://www.ema.europa.eu/en/medicines/human/EPAR/vargatef>, <https://en.wikipedia.org/wiki/Nintedanib>, <https://www.nice.org.uk/guidance/ta347> ;
  onco:status "approved" ;
  onco:tag "failure", "lesson:phase-2-pfs-signal" ;
  onco:modality "Small-molecule kinase inhibitor (VEGFR/FGFR/PDGFR)" ;
  schema:alternateName "Ofev (fibrosis); Vargatef (NSCLC, EU)" ;
  onco:approval "EU 2014: Adenocarcinoma NSCLC after first-line chemotherapy, with docetaxel", "US 2014: Idiopathic pulmonary fibrosis (non-oncology)", "England (NICE) 2015: Locally advanced, metastatic or locally recurrent non-small-cell lung cancer of adenocarcinoma histology progressing after first-line chemotherapy, with docetaxel" ;
  onco:cancers <https://onco.cc/cancers/mesothelioma/>, <https://onco.cc/cancers/lung-cancer/>, <https://onco.cc/cancers/lung-adenocarcinoma/> ;
  onco:technologies <https://onco.cc/technologies/antiangiogenic/>, <https://onco.cc/technologies/kinase-inhibitors/> ;
  onco:targets <https://onco.cc/targets/vegf/>, <https://onco.cc/targets/fgfr2/> ;
  onco:companies <https://onco.cc/companies/boehringer-ingelheim/> ;
  onco:trials <https://onco.cc/trials/lume-meso/> .